Background FOLFOX chemotherapy is one of the most commonly used treatments for
colorectal cancer (CRC) patients. However, the efficacy and tolerance of FOLFOX therapy …

Background FBXW7 is recognized as a critical tumor suppressor gene and a component of
the ubiquitin-proteasome system, mediating the degradation of multiple oncogenic proteins …

Colorectal cancer (CRC) is a human malignancy which associates with high mortality rate
and poor prognosis. Despite the initial effectiveness in clinical applications of …

Objective: 5-fluorouracil-and oxaliplatin-based FOLFOX regimens are mainstay
chemotherapeutics for colorectal cancer (CRC) but drug resistance represents a major …

Although the cancer stem cell (CSC) concept has provided a reasonable explanation for
cancer recurrence following chemotherapy, the relationship between CSCs and …

Background Various studies investigating the clinical significance of FBXW7 mutation and/or
expression have yielded inconclusive results in colorectal cancer (CRC) patients. Therefore …

FBXW7 is a potential tumor suppressor that regulates ubiquitination and proteolysis of
multiple targets such as cyclin E, c-Myc, c-Jun and Notch. However, little knows about the …

Background FBXW7 functions as a ubiquitin ligase tagging multiple dominant oncogenic
proteins and commonly mutates in colorectal cancer. Data suggest missense mutations lead …

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths globally.
Metastasis is associated with a poor prognosis, yet the underlying molecular mechanism (s) …

FBXW7 mutations occur in a variety of human cancers including colorectal cancer (CRC).
Elucidating its mechanism of action has become crucial for cancer therapy; however, it is …